Synthesis, biological evaluation, and computational studies of Tri- and tetracyclic nitrogen-bridgehead compounds as potent dual-acting AChE inhibitors and h H3 receptor antagonists

ACS Chemical Neuroscience

Volumn 5, Issue 3, 2014, Pages 225-242

  Darras, Fouad H ^a   Pockes, Steffen ^a   Huang, Guozheng ^c   Wehle, Sarah ^c   Strasser, Andrea ^b   Wittmann, Hans Joachim ^b   Nimczick, Martin ^c   Sotriffer, Christoph A ^c   Decker, Michael ^c  

^a Institut fur Pharmazie   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer's disease; docking; MD simulation

Indexed keywords

10 (3 BROMOPROPOXY) 13 METHYL 13,13A DIHYDRO 5H ISOQUINOLINO[1,2 B]QUINAZOLIN 8(6H) ONE; 10 (BENZYLOXY) 13 METHYL 13,13A DIHYDRO 5H ISOQUINOLINO[1,2B]QUINAZOLIN 8(6H) ONE; 10 HYDROXY 13 METHYL 13,13A DIHYDRO 5H ISOQUINOLINO [1,2 B]QUINAZOLIN 8(6H) ONE; 10 [(6 BROMOHEXYL)OXY] 13 METHYL 13,13A DIHYDRO 5H ISOQUINOLINO[1,2 B]QUINAZOLIN 8(6H) ONE; 10 [3 (AZEPAN 1 YL)PROPOXY] 13 METHYL 13,13A DIHYDRO 5H ISOQUINOLINO[1,2 B]QUINAZOLIN 8(6H) ONE; 10 [3 (AZEPAN 1 YL)PROPOXY] 13 METHYL 6,8,13,13A TETRAHYDRO 5H ISOQUINOLINO[1,2 B]QUINAZOLINE; 13 METHYL 10 (3 MORPHOLINOPROPOXY) 13,13A DIHYDRO 5H ISOQUINOLINO[1,2 B]QUINAZOLIN 8(6H) ONE; 13 METHYL 10 [3 (PIPERIDIN 1 YL)PROPOXY] 13,13A DIHYDRO 5H ISOQUINOLINO[1,2 B]QUINAZOLIN 8(6H) ONE; 13 METHYL 10 [3 (PIPERIDIN 1 YL)PROPOXY] 6,8,13,13A TETRAHYDRO13 METHYL 10 TETRAHYDRO 5H ISOQUINAZOLINO[1,2 B]QUINAZOLINE; 13 METHYL 10 [3 (PYRROLIDIN 1 YL)PROPOXY] 13,13A DIHYDRO 5H ISOQUINOLINO[1,2 B]QUINAZOLIN 8(6H) ONE; 13 METHYL 10 [3 (PYRROLIDIN 1 YL)PROPOXY] 6,8,13,13A TETRAHYDRO 5H ISOQUINOLINO[1,2 B]QUINAZOLINE; 13 METHYL 10 [[6 (PIPERIDIN 1 YL)HEXYL]OXY] 6,8,13,13A TETRAHYDRO 5H ISOQUINOLINO[1,2 B]QUINAZOLINE; 4 [3 [(13 METHYL 6,8,13,13A TETRAHYDRO 5H ISOQUINOLINO [1,2 B]QUINAZOLIN 10YL)OXY]PROPYL]MORPHOLINE; 6 AMINO 3 BENZYLOXY N ETHOXYCARBONYLBENZOIC ACID; 6 BENZYLOXYISATOIC ANHYDRIDE; 7 (3 BROMOPROPOXY) 2,3 DIHYDROPYRROLO[2,1 B]QUINAZOLIN 9(1H) ONE; 7 (BENZYLOXY) 2,3 DIHYDROPYRROLO[2,1 B]QUINAZOLIN 9(1H) ONE; 7 HYDROXY 2,3 DIHYDROPYRROLO[2,1 B]QUINAZOLIN 9(1H) ONE; 7 [3 (AZEPAN 1 YL)PROPOXY] 2,3 DIHYDROPYRROLO[2,1 B]QUINAZOLIN 9(1H) ONE; 7 [3 (PIPERIDIN 1 YL)PROPOXY] 1,2,3,3A,4,9 HEXAHYDROPYRROLO[2,1 B]QUINAZOLINE; 7 [3 (PIPERIDIN 1 YL)PROPOXY] 2,3 DIHYDROPYRROLO[2,1 B]QUINAZOLIN 9(1H) ONE; 7 [3 (PYRROLIDIN 1 YL)PROPOXY] 2,3 DIHYDROPYRROLO[2,1 B]QUINAZOLIN 9(1H) ONE; 7 [[6 (PIPERIDIN 1 YL)HEXYL]OXY] 1,2,3,9 TETRAHYDROPYRROLO[2,1 B]QUINAZOLINE; 7 [[6 (PIPERIDIN 1 YL)HEXYL]OXY] 2,3 DIHYDROPYRROLO[2,1 B]QUINAZOLIN 9(1H) ONE; ACETYLCHOLINE; CHOLINESTERASE INHIBITOR; HISTAMINE H3 RECEPTOR ANTAGONIST; NITROGEN DERIVATIVE; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ACETYLCHOLINESTERASE; GUANOSINE TRIPHOSPHATASE; HISTAMINE H1 RECEPTOR; HISTAMINE H2 RECEPTOR; HISTAMINE H3 RECEPTOR; HISTAMINE RECEPTOR;

ARTICLE; BINDING AFFINITY; BINDING SITE; CHOLINESTERASE INHIBITION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TARGETING; IC 50; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PHARMACOPHORE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; RADIOASSAY; SYNTHESIS;

ACETYLCHOLINESTERASE; BINDING SITES; CHOLINESTERASE INHIBITORS; GTP PHOSPHOHYDROLASES; HISTAMINE H3 ANTAGONISTS; HUMANS; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; MOLECULAR STRUCTURE; NITROGEN COMPOUNDS; RADIOLIGAND ASSAY; RECEPTORS, HISTAMINE; RECEPTORS, HISTAMINE H1; RECEPTORS, HISTAMINE H2; RECEPTORS, HISTAMINE H3;

EID: 84896446908     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn4002126     Document Type: Article

References (60)

1. Maslow, K. (2010) 2010 Alzheimer's disease facts and figures Alzheimer's Dementia 6, 158-194
2. Qiu, C., De Ronchi, D., and Fratiglioni, L. (2007) The epidemiology of the dementias: an update Curr. Opin. Psychiatry 20, 380-385
3. Reitz, C., Brayne, C., and Mayeux, R. (2011) Epidemiology of Alzheimer disease Nat. Rev. Neurol. 7, 137-152
4. Brookmeyer, R., Johnson, E., Ziegler-Graham, K., and Arrighi, H. M. (2007) Forecasting the global burden of Alzheimer's disease Alzheimer's Dementia 3, 186-191
5. Davies, P. and Maloney, A. J. F. (1976) Selective loss of central cholinergic neurons in Alzheimer's disease Lancet 308, 1403
6. 3 receptor: an attractive target for the treatment of cognitive disorders Br. J. Pharmacol. 154, 1166-1181
7. 3) of histamine receptor Nature 302, 832-837
8. 3 Receptor as a Drug Discovery Target J. Med. Chem. 54, 26-53
9. 3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders Mol. Interventions 6, 77-88
10. 3 Receptor Function and Ligands: Recent Developments Mini-Rev. Med. Chem. 13, 47-57
11. 3 antagonist and serotonin transporter inhibitors Bioorg. Med. Chem. Lett. 17, 2603-2607
12. 3 receptor antagonists derived from ligand based design Bioorg. Med. Chem. Lett. 17, 3670-3675
13. 3 receptor antagonists with potent cognition enhancing activity J. Med. Chem. 55, 414-423
14. Chen, X., Zenger, K., Lupp, A., Kling, B., Heilmann, J., Fleck, C., Kraus, B., and Decker, M. (2012) Tacrine-Silibinin codrug shows neuro- and hepatoprotective effects in vitro and pro-cognitive and hepatoprotective effects in vivo J. Med. Chem. 55, 5231-5242
15. Chen, X. and Decker, M. (2013) Multi-target compounds acting in the central nervous system designed from natural products Curr. Med. Chem. 20, 1673-1685
16. Decker, M. (2007) Recent advances in the development of hybrid molecules/designed multiple compounds with antiamnesic properties Mini-Rev. Med. Chem. 7, 221-229
17. Bajda, M., Guzior, N., Ignasik, M., and Malawska, B. (2011) Multi-target-directed ligands in Alzheimer's disease treatment Curr. Med. Chem. 18, 4949-4975
18. 3 receptor antagonists as potential procognitive agents Pharmazie 61, 179-182
19. Blackard, W. G. J., Sood, G. K., Crowe, D. R., and Fallon, M. B. (1998) Tacrine: A cause of fatal hepatotoxicity? J. Clin. Gastroenterol. 26, 57-59
20. Melo, T., Videira, R. A., André, S., Maciel, E., Francisco, C. S., Oliveira-Campos, A. M., Rodrigues, L. M., Domingues, M. R. M., Peixoto, F., and Manuel Oliveira, M. (2012) Tacrine and its analogues impair mitochondrial function and bioenergetics: a lipidomic analysis in rat brain J. Neurochem. 120, 998-1013
21. 3 receptor antagonists from molecular modeling Bioorg. Med. Chem. 16, 2968-2973
22. 3 receptor antagonists with moderate anti-cholinesterase activity Bioorg. Med. Chem. 16, 9911-9924
23. 3 Receptor Antagonistic and Anticholinesterase Activity Arch. Pharm. 345, 591-597
24. Darras, F. H., Kling, B., Heilmann, J., and Decker, M. (2012) Neuroprotective tri- and tetracyclic BChE inhibitors releasing reversible inhibitors upon carbamate transfer ACS Med. Chem. Lett. 3, 914-919
25. Roos, G. H. P. and Drastlik, K. A. (2003) Approach to the synthesis of (+)-Ifforestine. Model studies directed at the tetracyclic framework Heterocycles 60, 2023-2044
26. Beutner, G. L., Kuethe, J. T., and Yasuda, N. (2007) A practical method for preparation of 4-hydroxyquinolinone esters J. Org. Chem. 72, 7058-7061
27. Takeuchi, H., Matsushita, Y., and Eguchi, S. (1991) Novel ring enlargement of lactams via quinazolinone annelation. A facile route to benzoannelated large-membered cyclic 1,5-diamines J. Org. Chem. 56, 1535-1537
28. Decker, M. (2005) Novel inhibitors of acetyl- and butyrylcholinesterase derived from the alkaloids dehydroevodiamine and rutaecarpine Eur. J. Med. Chem. 40, 305-313
29. Yücel, Y. Y., Tacal, Ö., and Özer, I. (2008) Comparative effects of cationic triarylmethane, phenoxazine and phenothiazine dyes on horse serum butyrylcholinesterase Arch. Biochem. Biophys. 478, 201-205
30. Karlsson, D., Fallarero, A., Brunhofer, G., Mayer, C., Prakash, O., Mohan, C. G., Vuorela, P., and Erker, T. (2012) The exploration of thienothiazines as selective butyrylcholinesterase inhibitors Eur. J. Pharm. Sci. 47, 190-205
31. Decker, M., Krauth, F., and Lehmann, J. (2006) Novel tricyclic quinazolinimines and related tetracyclic nitrogen bridgehead compounds as cholinesterase inhibitors with selectivity towards butyrylcholinesterase Bioorg. Med. Chem. 14, 1966-1977
32. o Protein Heterotrimers J. Pharmacol. Exp. Ther. 332, 996-1005
33. 2 receptor antagonist. Poster at Frontiers in Medicinal Chemistry, a Joint German-Swiss Meeting, Saarbrücken, Germany.
34. 3 receptor function by monovalent ions Neurosci. Lett. 472, 114-118
35. The PyMOL Molecular Graphics System, Version 1.6.0.0, Schrödinger, LLC.
36. Cheung, J., Rudolph, M. J., Burshteyn, F., Cassidy, M. S., Gary, E. N., Love, J., Franklin, M. C., and Height, J. J. (2012) Structures of Human Acetylcholinesterase in Complex with Pharmacologically Important Ligands J. Med. Chem. 55, 10282-10286
37. a Prediction Method Using Grid Molecular Interaction Fields J. Chem. Inf. Model. 47, 2172-2181
38. 3 receptor for ligand docking and pharmacophore-based screening J. Comput.-Aided Mol. Des.. 21, 437-453
39. 3 receptor heterogeneity Neuropharmacology 44, 773-786
40. 3-receptors Biochem. Pharmacol. 80, 1437-1449
41. 3 receptor antagonists with a rigid biphenyl scaffold Bioorg. Med. Chem. Lett. 16, 4063-4067
42. Lim, H. D., Jongejan, A., Bakker, R. A., Haaksma, E., de Esch, I. J. P., and Leurs, R. (2008) Phenylalanine 169 in the Second Extracellular Loop of the Human Histamine H4 Receptor Is Responsible for the Difference in Agonist Binding between Human and Mouse H4 Receptors J. Pharmacol. Exp. Ther. 327, 88-96
43. Seifert, R., Strasser, A., Schneider, E. H., Neumann, D., Dove, S., and Buschauer, A. (2013) Molecular and cellular analysis of human histamine receptor subtypes Trends Pharmacol. Sci. 34, 33-58
44. Strasser, A., Wittmann, H.-J., Buschauer, A., Schneider, E. H., and Seifert, R. (2013) Species-dependent activities of G-protein-coupled receptor ligands: lessons from histamine receptor orthologs Trends Pharmacol. Sci. 34, 13-32
45. Lee-Dutra, A., Arienti, K. L., Buzard, D. J., Hack, M. D., Khatuya, H., Desai, P. J., Nguyen, S., Thurmond, R. L., Karlsson, L., Edwards, J. P., and Breitenbucher, J. G. (2006) Identification of 2-arylbenzimidazoles as potent human histamine H4 receptor ligands Bioorg. Med. Chem. Lett. 16, 6043-6048
46. Marson, C. M. (2011) Targeting the Histamine H4 Receptor Chem. Rev. 111, 7121-7156
47. Shimamura, T., Shiroishi, M., Weyand, S., Tsujimoto, H., Winter, G., Katritch, V., Abagyan, R., Cherezov, V., Liu, W., Han, G. W., Kobayashi, T., Stevens, R. C., and Iwata, S. (2011) Structure of the human histamine H1 receptor complex with doxepin Nature 475, 65-70
48. Angel, T. E., Chance, M. R., and Palczewski, K. (2009) Conserved waters mediate structural and functional activation of family A (rhodopsin-like) G protein-coupled receptors Proc. Natl. Acad. Sci. U.S.A. 106, 8555-8560
49. Liu, W., Chun, E., Thompson, A. A., Chubukov, P., Xu, F., Katritch, V., Han, G. W., Roth, C. B., Heitman, L. H., IJzerman, A. P., Cherezov, V., and Stevens, R. C. (2012) Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions Science 337, 232-236
50. Straßer, A., Striegl, B., Wittmann, H.-J., and Seifert, R. (2008) Pharmacological Profile of Histaprodifens at Four Recombinant Histamine H1 Receptor Species Isoforms J. Pharmacol. Exp. Ther. 324, 60-71
51. Igel, P., Geyer, R., Strasser, A., Dove, S., Seifert, R., and Buschauer, A. (2009) Synthesis and Structure-Activity Relationships of Cyanoguanidine-Type and Structurally Related Histamine H4 Receptor Agonists J. Med. Chem. 52, 6297-6313
52. Verdonk, M. L., Cole, J. C., Hartshorn, M. J., Murray, C. W., and Taylor, R. D. (2003) Improved protein-ligand docking using GOLD Proteins 52, 609-623
53. Molecular Operating Environment (MOE), 2011.10; Chemical Computing Group Inc., 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2011.
54. Jones, G., Willett, P., and Glen, R. C. (1995) Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation J. Mol. Biol. 245, 43-53
55. Jones, G., Willett, P., Glen, R. C., Leach, A. R., and Taylor, R. (1997) Development and validation of a genetic algorithm for flexible docking J. Mol. Biol. 267, 727-748
56. 1-receptor J. Pharmacol. Exp. Ther. 305, 1104-1115
57. 2-receptor with guanidine-type agonists Mol. Pharmacol. 60, 1210-1225
58. Schnell, D. B. I., Ladova, K., Schneider, E., Igel, P., Dove, S., Buschauer, A., and Seifert, R. (2011) Expression and functional properties of canine, rat and murine histamine H4 receptors in Sf9 insect cells Naunyn-Schmiedeberg's Arch. Pharmacol. 383, 457-470
59. 2 receptor agonists: synthesis and structure-activity relationships of mono and bivalent ligands. Ph.D. Dissertation, University of Regensburg, Germany.
60. 4 Receptor Ligands Arch. Pharm. 10.1002/ardp.201300316